Saundra Pelletier, Evofem CEO

Evofem's ap­proved birth con­trol gel flops PhI­II for STI pre­ven­tion, ear­ly 2023 fil­ing plans ditched

A biotech with an ap­proved non-hor­mon­al birth con­trol gel had hoped it would be at the FDA’s doorsteps in ear­ly 2023 to re­quest a la­bel …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.